Rituximab to treat ANCA-associated vasculitis;Rituximab et traitement des vascularites associées aux anticorps anticytoplasme des polynucléaires neutrophiles (ANCA)

Revue de Medecine Interne

Volumn 32, Issue 10, 2011, Pages 591-593

  Guillevin, L ^a   Mahr, A ^b  

^a Institut Cochin   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

ANCA; Anti CD20; Rituximab; Vasculitis

Indexed keywords

RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; ARTICLE; DRUG EFFICACY;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS;

EID: 80053177314     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2011.07.001     Document Type: Article

References (17)

1. Frohnert P.P., Sheps S.G. Long-term follow-up study of periarteritis nodosa. Am J Med 1967, 43:8-14.
2. Hollander D., Manning R.T. The use of alkylating agents in the treatment of Wegener's granulomatosis. Ann Intern Med 1967, 67:393-398.
3. Walton E.W. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958, 2:265-270.
4. Fauci A.S., Wolff S.M., Johnson J.S. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med 1971, 285:1493-1496.
5. Leib E.S., Restivo C., Paulus H.E. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 1979, 67:941-947.
6. Novack S.N., Pearson C.M. Cyclophosphamide therapy in Wegener's granulomatosis. N Engl J Med 1971, 284:938-942.
7. Sack M., Cassidy J.T., Bole G.G. Prognostic factors in polyarteritis. J Rheumatol 1975, 2:411-420.
8. Josselin L., Mahr A., Cohen P., Pagnoux C., Guaydier-Souquieres G., Hayem G., et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis 2008, 67:1343-1346.
9. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005, 352:351-361.
10. Jones R.B., Tervaert J.W., Hauser T., Luqmani R., Morgan M.D., Peh C.A., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363:211-220.
11. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232.
12. Flossmann O., Berden A., de Groot K., Hagen C., Harper L., Heijl C., et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011, 70:488-494.
13. Tomasson G., Grayson P.C., Mahr A., LaValley M., Merkel P.A. Value of ANCA measurements during remission to predict a relapse of ANCA-AAV: a meta-analysis. Clin Exp Immunol 2011, 164(66). [Abstract].
14. Specks U, Stone JH, and the RAVE/Immune Tolerance Network Working Group. Long-term efficacy of rituximab in ANCA-associated vasculitis. Ann Rheum Dis 2011 [Abstract].
15. van Oers M.H., Van Glabbeke M., Giurgea L., Klasa R., Marcus R.E., Wolf M., et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010, 28:2853-2858.
16. Tarella C., Passera R., Magni M., Benedetti F., Rossi A., Gueli A., et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 2011, 29:814-824.
17. Guillevin L. Clinical trials on systemic necrotizing vasculitides. Presse Med 2010, 39:643-649.